Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 2
2012 2
2013 2
2015 2
2016 2
2018 1
2019 1
2020 4
2021 4
2022 2
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.
Shacham-Abulafia A, Volcheck Y, Ellis M, Shapira S, Tavor S, Gourevitch A, Kreiniz N, Stanevski A, Raanani P, Koren-Michowitz M. Shacham-Abulafia A, et al. Eur J Haematol. 2024 Oct 21. doi: 10.1111/ejh.14330. Online ahead of print. Eur J Haematol. 2024. PMID: 39433446
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies.
Shapira S, Kazanov D, Mdah F, Yaakobi H, Herishanu Y, Perry C, Avivi I, Itchaki G, Shacham-Abulafia A, Raanani P, Hay-Levy M, Aiger G, Mashiah J, Lev-Ari S, Arber N. Shapira S, et al. Among authors: shacham abulafia a. J Pers Med. 2021 Jul 27;11(8):724. doi: 10.3390/jpm11080724. J Pers Med. 2021. PMID: 34442367 Free PMC article.
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study.
Duek A, Tzinman A, Maziuk K, Levy A, Ellis M, Stemer G, Shacham Abulafia A, Cohen A, Lavi N, Ronson A, Braester A, Shapira S, Canaani J, Volchek Y, Leiba R, Leiba M. Duek A, et al. Among authors: shacham abulafia a. Acta Haematol. 2024 Sep 12:1-7. doi: 10.1159/000540906. Online ahead of print. Acta Haematol. 2024. PMID: 39265539
22 results